Fig. 6: PPA1 restricts JNK activation to mediate NSCLC tumor progression in vitro.
From: PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner
a Western Blot was used to detect the expression of JNK, ERK, p38, and their activation form, β-actin was included as a loading control. b Flow cytometry assay was performed on NCI-H460 silencing PPA1 with or without adding JNK420119. c Up panel: the statistical result of the flow cytometry analysis. Asterisks represent p-values < 0.05. Down panel: western blot was used to detect the expression of P-JNK and Caspase3 in NCI-H460 silencing PPA1 with or without adding JNK420119. d The cell growth of NCI-H460 with silencing PPA1 after added or not added JNK420119 were analyzed at 0, 24, 48, 72, and 96 h after cell seeding, NCI-H460 SC as negative control. e The immunoblot showed the expression of Ki67 in NCI-H460 silencing PPA1 with or without adding JNK420119, β-actin was included as a loading control. f BrdU-7AAD double staining assay was performed on NCI-H460 silencing PPA1 with or without adding JNK420119. g The statistical results of S stage percentage in NCI-H1299 silencing PPA1 with or without adding JNK420119.
